Regorafenib

While everyone is hyperventilating over the merits or otherwise of the new Head of the Americas region, I thought that this news item is potentially more relevant.  Comments anyone?   At the least I would suggest that another trial is on the cards to compare SIRT vs regorafenib?   More research dollars spent shoring up market share....

http://www.prnewswire.com/news-rele...-of-improving-overall-survival-300262856.html

Bayer today announced that a Phase III trial evaluating its oncology compound Stivarga® (regorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC) has met its primary endpoint of a statistically significant improvement in overall survival. The study, called RESORCE, evaluated the efficacy and safety of regorafenib in patients with HCC whose disease has progressed after treatment with sorafenib. The safety and tolerability were generally consistent with the known profile of regorafenib.  Detailed efficacy and safety analyses from this study are expected to be presented at an upcoming scientific congress.
"Effective treatment options are urgently needed for patients with unresectable liver cancer," said Dr. Joerg Moeller, member of the Executive Committee of Bayer AG's Pharmaceutical Division and Head of Development. "With sorafenib having been the only systemic option for the treatment of unresectable HCC since 2007, regorafenib could now become the second proven systemic option. We would like to thank the patients and the study investigators for their contributions and participation in this study."
Bayer plans to submit data from the RESORCE study as the basis for marketing authorization of regorafenib in the treatment of unresectable HCC in 2016.